According to the Huayuan Securities Research Report, Corfu Healthcare's core products have maintained relatively rapid growth, and the overseas product matrix has been further enriched. 2026H1 net profit to mother was 202 million yuan, +20.84% year on year; 2026Q2 net profit to mother was 95 million yuan, +25.35% year over year. Core single products have maintained relatively rapid growth, and new incremental products are about to be launched. Overall, the revenue growth rate of the top five core products in 2026H1 reached 50%. At the same time, new products such as CGM and Philips authorized products will soon be launched, which is expected to become an important source of growth for the company in the future. By channel, the company achieved online revenue of 1,433 billion yuan in 2026H1, +47.07% year-on-year; offline revenue of 584 million yuan, +23.19% year-on-year. The overseas product matrix has been further enriched, and revenue continues to rise. As a leading household medical device company, Kefu Medical is actively platform-based. It is expected to continue to focus on core products in the future. The product pipeline is rich, profitability is expected to increase rapidly, and maintain the company's “buy” rating.

According to the Huayuan Securities Research Report, Corfu Healthcare's core products have maintained relatively rapid growth, and the overseas product matrix has been further enriched. 2026H1 net profit to mother was 202 million yuan, +20.84% year on year; 2026Q2 net profit to mother was 95 million yuan, +25.35% year over year. Core single products have maintained relatively rapid growth, and new incremental products are about to be launched. Overall, the revenue growth rate of the top five core products in 2026H1 reached 50%. At the same time, new products such as CGM and Philips authorized products will soon be launched, which is expected to become an important source of growth for the company in the future. By channel, the company achieved online revenue of 1,433 billion yuan in 2026H1, +47.07% year-on-year; offline revenue of 584 million yuan, +23.19% year-on-year. The overseas product matrix has been further enriched, and revenue continues to rise. As a leading household medical device company, Kefu Medical is actively platform-based. It is expected to continue to focus on core products in the future. The product pipeline is rich, profitability is expected to increase rapidly, and maintain the company's “buy” rating.